Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 228Neoplasm Metastasis 17Breast Neoplasms, Male 7Breast Diseases 7Neoplasms 6Carcinoma, Intraductal, Noninfiltrating 4Recurrence 3Obesity 3Breast Carcinoma In Situ 3Breast Cancer Metastatic 3Advanced Breast Cancer 3Neoplasms by Site 2Bulbo-Spinal Atrophy, X-Linked 2Arthralgia 2Vitamin D Deficiency 1Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sleep Wake Disorders 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Primary Breast Cancer ER+ve 1Premenopausal Breast Cancer 1Post Menopausal Women With Early Breast Cancer 1Patient Acceptance of Health Care 1Pain 1

Interventions

Cyclophosphamide 6Radiotherapy 5olaparib 3exemestane 3Paclitaxel 3Letrozole 3Itraconazole 3Gemcitabine 3Fulvestrant 3Carboplatin 3Blood Specimen Collection 3palbociclib 2fludarabine phosphate 2eribulin 2avelumab 2abemaciclib 2Therapeutics 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Mastectomy 2Flow Cytometry 2Filgrastim 2Exercise 2Everolimus 2Etoposide 2Dasatinib 2Cetuximab 2Carmustine 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × exemestane × Breast × Clear all
NCT07062965 2026-05-06

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Pfizer

Phase 3 Recruiting
400 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Pfizer

Phase 2 Active not recruiting
333 enrolled
Breast

Breast Neoplasms, Recurrence

NCT04666805 2020-12-14

Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast

First Hospital of China Medical University

Unknown
1,354 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡